A detailed history of Barclays PLC transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 228 shares of RPHM stock, worth $383. This represents 0.0% of its overall portfolio holdings.

Number of Shares
228
Previous 228 -0.0%
Holding current value
$383
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$1.34 - $1.7 $243 - $309
182 Added 395.65%
228 $0
Q2 2024

Aug 14, 2024

SELL
$1.51 - $1.9 $12,249 - $15,412
-8,112 Reduced 99.44%
46 $0
Q1 2024

May 15, 2024

SELL
$1.59 - $1.74 $25,880 - $28,321
-16,277 Reduced 66.61%
8,158 $13,000
Q4 2023

Feb 15, 2024

SELL
$1.34 - $8.43 $71,935 - $452,547
-53,683 Reduced 68.72%
24,435 $38,000
Q3 2023

Nov 07, 2023

BUY
$5.44 - $8.13 $23,087 - $34,503
4,244 Added 5.74%
78,118 $595,000
Q2 2023

Aug 03, 2023

BUY
$5.44 - $10.5 $10,575 - $20,412
1,944 Added 2.7%
73,874 $484,000
Q3 2022

Nov 03, 2022

BUY
$2.35 - $4.85 $42,262 - $87,222
17,984 Added 33.34%
71,930 $241,000
Q2 2022

Aug 12, 2022

BUY
$1.96 - $3.04 $98,752 - $153,167
50,384 Added 1414.49%
53,946 $143,000
Q1 2022

May 16, 2022

BUY
$2.94 - $9.07 $10,472 - $32,307
3,562 New
3,562 $10,000

Others Institutions Holding RPHM

About Reneo Pharmaceuticals, Inc.


  • Ticker RPHM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,479,600
  • Market Cap $41.1M
  • Description
  • Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...
More about RPHM
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.